Phase II crinical trial of cetuximab rechallenge with KRAS wild-type unresectable/recurrent colorectal cancer

ABSTRACT: Interventions: This is a multicentric phase II trial that examines patients who had a clinical benefit [confirmed stable disease (SD) for at least 6 months or clinical response] after a line of cetuximab- plus FOLFOX/FOLFIRI therapy and then a progression of disease, during cetuximab-based therapy, for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same or another Cetuximab based chemotherapy. Primary outcome(s): Response rate(RR) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2625092 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR